Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company specializing in targeted therapies for RAS-driven cancers, has announced promising early data on RMC-9805, a selective inhibitor for the RAS(ON) G12D mutation. The preliminary safety and antitumor results for RMC-9805 were…
This study investigates the rise of AI-based drug repurposing and assesses the factors that drive or hinder its adoption. Traditional drug discovery methods have limitations that fuel interest in AI-based approaches, which promise significant advantages in terms of time, efficiency,…
GeneDx’s GUARDIAN Study Reveals Promise of Whole Genome Sequencing for Newborns Recent findings published in the Journal of the American Medical Association (JAMA) underscore the limitations of traditional newborn screening methods while highlighting the potential of advanced genomic technology to…
Havah Therapeutics, a clinical-stage biopharmaceutical company focused on innovative hormonal implant therapies for breast cancer prevention and treatment, has established a Clinical Advisory Board chaired by founder Stephen Birrell, MD, PhD. This board comprises experts in breast cancer biology, endocrine…
AU-007 Showcases Unique IL-2 Class Profile with Promising Efficacy Data Aulos Bioscience, a pioneering company in the field of immuno-oncology, recently presented significant data supporting the dose selection for its lead therapeutic candidate, AU-007, at the 36th EORTC-NCI-AACR Symposium on…
Bioptimus’ H-optimus-0 Model Now Integrated with Proscia’s Concentriq® for Fast AI Development Bioptimus, a leading French AI startup, has announced the integration of its H-optimus-0 foundation model into Proscia’s Concentriq® Embeddings platform. With 1.1 billion parameters, H-optimus-0 is the largest…
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® in First-Line Treatment of Gastric, Gastroesophageal, and Esophageal Cancers BeiGene, a global oncology leader, has achieved a significant milestone with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issuing…
Bruker Unveils Groundbreaking $100 Plasma Proteomics Platform, Pioneering Advances in Glycoproteomics and Metaproteomics Bruker Corporation has announced a revolutionary leap in 4D-Proteomics™, offering deep, high-fidelity plasma proteomics for just $100 per sample, marking a significant step forward in large-scale, unbiased…
NUCLIDIUM Announces First Patient Imaged in Phase 1 Study of ⁶¹Cu Radiotracer for Prostate Cancer NUCLIDIUM has successfully imaged the first patient in its Phase 1 clinical trial evaluating ⁶¹Cu-NuriPro™ (⁶¹Cu-NODAGA-PSMA I&T), a radiotracer designed to safely and accurately diagnose…
Celltrion has announced two-year findings from a post-hoc analysis of the LIBERTY studies (LIBERTY-CD and LIBERTY-UC), presented at United European Gastroenterology (UEG) Week 2024 in Vienna. The analysis shows that dose escalation of subcutaneous infliximab (CT-P13 SC) is effective for…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has shared positive results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, an investigational monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) during their first…
Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has launched Medidata Rave Lite, an extension of its flagship clinical research software, Medidata Rave EDC. Designed specifically for Phase I and IV…